WO1991007963A1 - Glycyl-p-amino-pyridine for the treatment of senile dementia states - Google Patents

Glycyl-p-amino-pyridine for the treatment of senile dementia states Download PDF

Info

Publication number
WO1991007963A1
WO1991007963A1 PCT/EP1990/002055 EP9002055W WO9107963A1 WO 1991007963 A1 WO1991007963 A1 WO 1991007963A1 EP 9002055 W EP9002055 W EP 9002055W WO 9107963 A1 WO9107963 A1 WO 9107963A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino
pyridine
treatment
glycyl
mice
Prior art date
Application number
PCT/EP1990/002055
Other languages
French (fr)
Inventor
Giuseppe Quadro
Original Assignee
Medea Research S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medea Research S.R.L. filed Critical Medea Research S.R.L.
Priority to AT90917637T priority Critical patent/ATE96319T1/en
Publication of WO1991007963A1 publication Critical patent/WO1991007963A1/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B24—GRINDING; POLISHING
    • B24B—MACHINES, DEVICES, OR PROCESSES FOR GRINDING OR POLISHING; DRESSING OR CONDITIONING OF ABRADING SURFACES; FEEDING OF GRINDING, POLISHING, OR LAPPING AGENTS
    • B24B23/00—Portable grinding machines, e.g. hand-guided; Accessories therefor
    • B24B23/02—Portable grinding machines, e.g. hand-guided; Accessories therefor with rotating grinding tools; Accessories therefor
    • B24B23/03—Portable grinding machines, e.g. hand-guided; Accessories therefor with rotating grinding tools; Accessories therefor the tool being driven in a combined movement
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • G lycyl-p-amino-pyridine for the treatment of senile dementia states .
  • the present invention relates to the use of glycyl-p-amino-pyridine monoacetate of formula I
  • a inopyridines affect the neurotransmitter release, by increasing it (Paskow et al., 1986) and at high dosages they induce convulsions.
  • Aminopyridines have been tested with favourable results in several clinical conditions ranging from diseases of neuromuscular transmission, including multiple sclerosis (Stefoski et al. , 1987), to recovery from anaesthesia (Lechat et al. , 1982; Pascow et al. , 1986).
  • Alzheimer's disease the patient's cerebral cortex is remarkably damaged owing to neurohistological variations fneurofibrillar variations, etc), generally against temporal and frontal lobes, with resulting intellectual function deterioration; the initial clinical picture appears with psychogenic disorders, anxiety and depression, followed by confusion, memory disorders, reduced comprehension and judgement capacity, until to a total patient absence.
  • the D 50 was calculated according to the method described by Litchfield and Wilcoxon (J. Pharmacol. Exp. Ther. 96, 99; 1949). Results Table 1
  • the symptoms preceeding death were agitation, aggressiveness, jerks, stretchings and tonic convul ⁇ sions.
  • MR-3066 showed a toxicity lower than 4- aminopiridine. Acute convulsant activity
  • MR-3066 resulted less convulsant than 4-aminopy- ridine.
  • mice Male mice (body weight ca 20 grams) were used.
  • the test apparatus was a box with a dark compartment and an illuminated one.
  • MR-3066 was intraperitoneally administered immediately after the acquisition trial.
  • MR-30-66 significantly prolonged the latency at the dose level of 5 mg/kg i.p.. The compound was indicated to facilitate learning behavior in normal mice.
  • % of control (the mean latency time of test compound treated mice/the mean latency time of vehicle treated mice) 100. P ⁇ 0.01 vs Control (0 mg/kg i.p.)
  • mice Male mice (body weight 23 - 26 grams) were used. Test apparatus and passive avoidance training
  • ECS electroconsulsive shock
  • MR-3066 significantly prolonged the latency at the dose levels of 1 and 2.5 mg/kg i.p..
  • Physostigmine significantly prolonged the latency at the doses of 0.025 and 0.05 mg/kg i.p. and THA at the dose of 2.5 mg/kg i.p. MR-3066 showed an anti-amnesic effect more potently than THA did.
  • ECS electroconvulsive shock
  • Anti-amnesic activity was calculated according to the following formula.
  • % of control (the mean latency time of test compound treated mice/the mean latency time of vehicle treated mice) x 100.
  • mice and passive avoidance training were as described in the previous sections (4.2 - 4.3).
  • the compounds were intraperitoneally administered 30 min. before the acquisition trial.
  • Amnesia was induced by scolopolamine (1 mg/kg s.c.) given 20 min. prior to the acquisition trial; the test trial was performed after 24 hours.
  • Anti-amnesic activity was calculated according to the following formula.
  • % of control (the mean latency time of test compound treated mice/the mean latency time of vehicle treated mice) x 100.
  • results MR-3066 (2 mg/kg i.v.) decreased fast wave activity in the motor cortex and increased theta activity in the hippocampus. The onset of the effects is five to 15 min. post administration, and their duration ranges from two to three hours.
  • MR-3066 showed effects similar to physostigmine, and the duration of action of the former compound is longer than that of the latter one.
  • MR-3066 was found to be still more effective than physostigmine.
  • the present invention refers to all the aspects which are industrially connected to the use of MR-3066 as active agent useful for the treatment of neurological and cerebral pathologies.
  • one essential aspect of the invention is constituted by pharmaceutical compositions containing MR-3066 alone or in admixture with one or more pharmaceutically acceptable carriers, in the shape of tablets, sugar-coated pills, pellets, injectables.
  • the pharmaceutical compositions of the present invention are preferably administered in doses ranging from 1 to 500 mg according to the pathology, the sex, and the age.
  • the organic phase is washed twice with a 1 sodium bicarbonate solution, then with water till neutral reaction, and dried on anhydrous sodiu sulphate.
  • the catalyst is filtered on Celite and the filtrate is evaporated to dryness.
  • the partially oily residue is recovered with diethyl ether and crystallizes spontaneously.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Mechanical Engineering (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Finish Polishing, Edge Sharpening, And Grinding By Specific Grinding Devices (AREA)

Abstract

A pharmaceutical composition (orally or parenterally administered) containing glycyl-p-amino-pyridine monoacetate alone or together suitable carriers, which shows surprising anti-amnesic and anti-Alzheimer properties, is described.

Description

Glycyl-p-amino-pyridine for the treatment of senile dementia states .
**
The present invention relates to the use of glycyl-p-amino-pyridine monoacetate of formula I
Figure imgf000003_0001
to prepare a medicament, which is particularly useful in the treatment of psychic and physical fatigue
10 syndromes, memory disturbances, senile deficiency, psychoinvolution, nervous breakdown, and the like.
The present compound, hereinafter named with the code MR-3066, was disclosed in Indian Journal of Chemistry 5/524 1967 and in El. Naggar et al.
15 J.Sci.Res.1986 4 (2) (473/83 pag) ; in this last paper the antibacterial, disinfectant and antiseptic properties of various amino-acyl-amino-pyridines and amino-acyl-amino-pyrimidines are described.
It has now been found that the compound MR-3066 is
20 endowed with anticonvulsivant properties, with effects on the cerebral acetylcholine release (without nevertheless showing Parkinson-like effect), with positive influence on learning and on amnesia episodes.
Therefore, the compound MR-3066 can be
25 advantageously used in neurologic medicine for the treatment of symptoms and syndromes such as, for instance, the Alzheimer's disease (or senile dementia), for which no specific drugs exist so far. A inopyridines affect the neurotransmitter release, by increasing it (Paskow et al., 1986) and at high dosages they induce convulsions.
Aminopyridines have been tested with favourable results in several clinical conditions ranging from diseases of neuromuscular transmission, including multiple sclerosis (Stefoski et al. , 1987), to recovery from anaesthesia (Lechat et al. , 1982; Pascow et al. , 1986). In Alzheimer's disease, the patient's cerebral cortex is remarkably damaged owing to neurohistological variations fneurofibrillar variations, etc), generally against temporal and frontal lobes, with resulting intellectual function deterioration; the initial clinical picture appears with psychogenic disorders, anxiety and depression, followed by confusion, memory disorders, reduced comprehension and judgement capacity, until to a total patient absence.
At the moment there is no effective therapy to treat this disease, which is considered to be irreversible.
The seriousness of the disease and its social impact justify clinical trials of rather toxic compounds, such as aminopyridines. It has been pointed out the remarkable contribution of the compound, if not to the resolution, at least to the lightening of the syndrome. TOXICOLOGIC AND PHARMACOLOGICAL EVALUATIONS 1) Acute toxicity The acute toxicity of MR-3066 was evaluated after oral administration of the drug to the Swiss mice versus 4-aminopyridine.
The D50 was calculated according to the method described by Litchfield and Wilcoxon (J. Pharmacol. Exp. Ther. 96, 99; 1949). Results Table 1
Figure imgf000005_0001
The symptoms preceeding death were agitation, aggressiveness, jerks, stretchings and tonic convul¬ sions.
MR-3066 showed a toxicity lower than 4- aminopiridine. Acute convulsant activity
The acute convulsant activity of MR-3066 and 4- aminopyridine was compared in Swiss male mice after oral administration.
The CD5Q (Convulsant Doses 50) were calculated according to the method described by Litchfield and Wilcoxon (J. Pharmacol. Exp. Ther. 96, 99; 1949). Results Table 2
Figure imgf000006_0001
MR-3066 resulted less convulsant than 4-aminopy- ridine.
Toxicity after repeated administration - Preliminary study
The toxicity of MR-3066 after repeated administration was evaluated in male and female Sprague Dawley rat after oral administration of the drug (6 mg/kg) for 30 consecutive days. Results
The oral administration of MR-3066 for 30 days to the rat brought no toxic phenomenon except from a slight decrease in body weight increase in the female accompanied by a reduction in food consumption.
No sign of treatment related toxicity was either assessed from the hystopathological findings. PHARMACOLOGY Effect on acetylcholine release from the rat's cerebral cortex "in vivo'1 1° study: Acute treatment
In this study the Acetylcholine release from the cerebral cortex was investigated in anesthetized rats (n=5) at different times before and after i.p. administration of MR-3066 at a dose of 5.6 mg/kg. Results
The i.p. administration of MR-3066 at the dose of 5.6 mg/kg was followed by a marked increase in Ach release, which reached a peak after 45* and then gradually decreased.
At this dose no tremor or muscolar jerk were observed. 2" study: Chronic treatment
Three male rats receiving MR-3066 at the oral dose of 6mg/kg for 30 consecutive days and then treated i.p. with 5.6 mg/kg of MR-3066, showed an increase in Ach release similar to that observed in animals receiving the drug under study for the first time; accordingly, the repeated oral administration of MR-3066 induces no tachyphylaxis.
Learning behavior in normal mice (Passive avoidance response)
Male mice (body weight ca 20 grams) were used. The test apparatus was a box with a dark compartment and an illuminated one.
The animal was placed in the illuminated compartment, foot-shock was given immediately after the mouse moved in the dark compartement (acquisition trial). MR-3066 was intraperitoneally administered immediately after the acquisition trial.
The test trial was carried out 24 h following the acquisition trial and the latency time to enter the dark compartment was recorded. Results (Table 3)
MR-30-66 significantly prolonged the latency at the dose level of 5 mg/kg i.p.. The compound was indicated to facilitate learning behavior in normal mice.
Table 3
Effect on the retention of passive avoidance response in mice (n=20)
Figure imgf000008_0001
Anti-amnesic activity was calculated acording to the following formula: % of control = (the mean latency time of test compound treated mice/the mean latency time of vehicle treated mice) 100. P<0.01 vs Control (0 mg/kg i.p.)
Effect on electroconvulsive shock - induced amnesia in mice
Male mice (body weight 23 - 26 grams) were used. Test apparatus and passive avoidance training
(acquisition trial) were as described in the previous section.
Immediately after acquisition trial, amnesia was induced by electroconsulsive shock (ECS). Test compounds, were administered intraperitoneally soon afterwards the exposure to ECS. The test trial was performed 24 h after the acquisition trial: the animals were put in the illuminated compartment an the latency time to enter the unlighted compartment was recorded. Results (Table 4)
MR-3066 significantly prolonged the latency at the dose levels of 1 and 2.5 mg/kg i.p.. Physostigmine significantly prolonged the latency at the doses of 0.025 and 0.05 mg/kg i.p. and THA at the dose of 2.5 mg/kg i.p. MR-3066 showed an anti-amnesic effect more potently than THA did.
Table 4
Effect on electroconvulsive shock (ECS) induced amnesia in mice (n=20)
Figure imgf000010_0001
Figure imgf000010_0002
Figure imgf000010_0003
Anti-amnesic activity was calculated according to the following formula.
% of control = (the mean latency time of test compound treated mice/the mean latency time of vehicle treated mice) x 100.
P < 0.05 P < 0.01 vs control. Effect on scopolamine - induced amnesia in mice
Test apparatus, mice and passive avoidance training (acquisition trial) were as described in the previous sections (4.2 - 4.3). The compounds were intraperitoneally administered 30 min. before the acquisition trial.
Amnesia was induced by scolopolamine (1 mg/kg s.c.) given 20 min. prior to the acquisition trial; the test trial was performed after 24 hours.
The animals were put in the illuminated compartment and latency time to enter the dark compartment was recorded. Results (Table 5) MR-3066 significantly prolonged the latency at the dose level of 1 mg/kg i.p. and physostimgmine at the dose of 0.1 mg/kg i.p..
Table 5
Effect on scopolamine-induced amnesia in mice
Figure imgf000012_0001
Figure imgf000012_0002
Anti-amnesic activity was calculated according to the following formula.
% of control = (the mean latency time of test compound treated mice/the mean latency time of vehicle treated mice) x 100.
•*f -ic ic
P < 0.05 P < 0.01 vs Controls. Spontaneous EEG in rabbits
Electrodes were chronically implanted in the motor cortex, the hippocampus and the nucleus amygdalae of rabbits (n=4).
The effects of compounds on spontaneous EEG were studied in the animals. Results MR-3066 (2 mg/kg i.v.) decreased fast wave activity in the motor cortex and increased theta activity in the hippocampus. The onset of the effects is five to 15 min. post administration, and their duration ranges from two to three hours.
Similar findings were observed immediately after the administration of physostigmine (0.1 mg/kg i.v.) and the effects lasted from 30 to 50 min.
MR-3066 showed effects similar to physostigmine, and the duration of action of the former compound is longer than that of the latter one. Transcallosal evoked potential in rats
Electric stimulus was given to the callosum of urethane anesthetized rats, and transcallosal evoked potential from the opposite side cerebral cortex was measured.
The effects of the compounds on the transcallosal evoked potential were studied in rats. Results .MR-3066 (2 mg/kg i.v.) and physostigmine (0.1 mg/kg i.v.) increased the amplitude of negative wave.
MR-3066 was found to be still more effective than physostigmine.
Both compounds raised the mean blood pressure, but the effect of physostigmine was much more marked than MR-3066.
The present invention refers to all the aspects which are industrially connected to the use of MR-3066 as active agent useful for the treatment of neurological and cerebral pathologies.
Therefore, one essential aspect of the invention is constituted by pharmaceutical compositions containing MR-3066 alone or in admixture with one or more pharmaceutically acceptable carriers, in the shape of tablets, sugar-coated pills, pellets, injectables. The pharmaceutical compositions of the present invention are preferably administered in doses ranging from 1 to 500 mg according to the pathology, the sex, and the age.
The following example further illustrates the invention.
EXAMPLE 5 g (23.9 moles) of carbobenzoxy-glycine dissolved
.'. " ' ' . -_ in tetrahydrofurane (150 ml) containing 1.9 ml of pyridine and 2.63 ml of N-methyl-morpholine, cooled to -15°C (ice/salt bath) are treated under stirring with 3.12 ml (21.9 moles) of isobutyl-chloroformate.
After 15 minutes 2.14 g of 4-amino-ρyridine are added, and the reaction mixture is kept under stirring overnight at room temperature, then the solvent is evaporated under low pressure and the residue is recovered with ethyl acetate and water.
The organic phase is washed twice with a 1 sodium bicarbonate solution, then with water till neutral reaction, and dried on anhydrous sodiu sulphate.
After solvent evaporation the residue i crystallized from ethyl acetate (hot/cold) , filtered, washed with diethyl ether ' and vacuum-dried. 4.2 (yield 66%) are obtained. M.P. 113-116°C. 3.5 g of glycyl-p-amino-pyridine, dissolved i about 100 ml of methanol containing 10% of acetic acid, are hydrogenated for about 3 hours in the presence of Pd/C.
The catalyst is filtered on Celite and the filtrate is evaporated to dryness. The partially oily residue is recovered with diethyl ether and crystallizes spontaneously.
The product is filtered and vacuum-dried. 1.8 g (yield 53%) are obtained. M.P. 182-184°C (dec. ) . ELEMENTAL ANALYSIS
C H N
% calculated 51,18 6,16 19,90 % found 51,49 6,31 19,89
NMR SPECTRA [Varian EM 390 -90 MHZ] (D20) CHEMICAL SHIFT MOLTEPLICITY INTEGRATION ATTRIBUTION
2.0 singlet 3H CH_3-C00H o
4.05 singlet 2H -C-CH_2-N
7.6 doublet 2H H H
8.5 doublet 2H
Figure imgf000015_0001

Claims

CLAIM
The use of glycyl-p-amino-pyridine monoacetate to prepare medicaments useful for the therapy of senile dementia syndromes (Alzheimer1disease) , elderly confusion disorders, amnesic states, nervous breakdown.
PCT/EP1990/002055 1989-12-04 1990-11-30 Glycyl-p-amino-pyridine for the treatment of senile dementia states WO1991007963A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT90917637T ATE96319T1 (en) 1989-12-04 1990-11-30 GLYCYL-P-AMINO-PYRIDINE FOR THE TREATMENT OF SENILE DEMENTIA.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT02259589A IT1242475B (en) 1989-12-04 1989-12-04 COLINERGIC AGENT, IN PARTICULAR GLYCIL-P-AMINO-PYRIDINE-ANYLIDE-MONOACETATE, FOR THE TREATMENT OF SENILE STATE OF DEEMENT.
IT22595A/89 1989-12-04

Publications (1)

Publication Number Publication Date
WO1991007963A1 true WO1991007963A1 (en) 1991-06-13

Family

ID=11198256

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1990/002055 WO1991007963A1 (en) 1989-12-04 1990-11-30 Glycyl-p-amino-pyridine for the treatment of senile dementia states

Country Status (10)

Country Link
US (1) US5244897A (en)
EP (1) EP0504180B1 (en)
JP (1) JP3181580B2 (en)
AT (1) ATE96319T1 (en)
AU (1) AU6873491A (en)
CA (1) CA2070376A1 (en)
DE (1) DE69004267T2 (en)
ES (1) ES2060207T3 (en)
IT (1) IT1242475B (en)
WO (1) WO1991007963A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7884079B2 (en) * 2004-12-27 2011-02-08 Miller Landon C G 4-aminopyridine and a pharmaceutical composition for treatment of neuronal disorders
US8691835B2 (en) 2004-12-27 2014-04-08 Landon C. G. Miller 4 aminopyridine and a pharmaceutical composition for treatment of neuronal disorders

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1932844T3 (en) * 2005-10-06 2015-12-31 Nippon Soda Co Cross-linked cyclic amine compounds and agents for pest control

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0308337A2 (en) * 1987-09-17 1989-03-22 Mitsubishi Kasei Corporation 4-Aminopyridine derivatives and their acid addition salts

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3615799C2 (en) * 1986-05-10 1994-10-13 Bosch Gmbh Robert Eccentric sander with a device for changing the grinding movement

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0308337A2 (en) * 1987-09-17 1989-03-22 Mitsubishi Kasei Corporation 4-Aminopyridine derivatives and their acid addition salts

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Arab. Gulf J. Scient. Res., volume 4, no. 2, 1986, A.M. El. Naggar et al.: "Synthesis and biological activity of some new 4-(aminoacyl)-aminopyridines and 2-(aminoacyl) Aminopyrimidine derivatives", pages 473-483 *
Biol. Psychiatry, vol. 23, 1988, Society of Biological Psychiatry, M. Davidson et al.: "4-Aminopyridine in the treatment of alzheimer's disease", pages 485-490 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7884079B2 (en) * 2004-12-27 2011-02-08 Miller Landon C G 4-aminopyridine and a pharmaceutical composition for treatment of neuronal disorders
US8691835B2 (en) 2004-12-27 2014-04-08 Landon C. G. Miller 4 aminopyridine and a pharmaceutical composition for treatment of neuronal disorders

Also Published As

Publication number Publication date
ES2060207T3 (en) 1994-11-16
EP0504180A1 (en) 1992-09-23
DE69004267D1 (en) 1993-12-02
AU6873491A (en) 1991-06-26
IT8922595A1 (en) 1991-06-04
ATE96319T1 (en) 1993-11-15
IT8922595A0 (en) 1989-12-04
EP0504180B1 (en) 1993-10-27
CA2070376A1 (en) 1991-06-05
DE69004267T2 (en) 1994-02-24
IT1242475B (en) 1994-03-17
JPH05502446A (en) 1993-04-28
US5244897A (en) 1993-09-14
JP3181580B2 (en) 2001-07-03

Similar Documents

Publication Publication Date Title
EP0734724B1 (en) Process for the preparation of a phencynonate hydrochloride of alpha-configuration
DE60110557T2 (en) AMINOADAMANTAN DERIVATIVES AS THERAPEUTIC AGENTS
DE69529897T3 (en) 42-RAPAMYCIN HYDROXYESTER, PROCESS FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF
EP2705037B1 (en) Substituted imidazopyridines and imidazopyridazines and use thereof
US4738985A (en) Pharmaceutical composition and treatment
CH623587A5 (en)
CN101402565B (en) Halogenated 2-(a-hydroxyl pentyl) benzoate, production method and uses thereof
JP2001504437A (en) Immunosuppressive compounds and methods
DE10057751A1 (en) New carbamate-substituted pyrazolo (3,4-b) pyridine derivatives, are soluble guanylate cyclase stimulants useful e.g. for treating cardiovascular or central nervous system diseases, sexual dysfunction or inflammation
CH631696A5 (en) METHOD FOR PRODUCING OLEFINIC DERIVATIVES FROM AMINO ACIDS.
DE2065635C3 (en) 10-Dioxo-11-methyldibenzothiazepine derivatives, processes for their production and pharmaceutical preparations containing them
CN108148106A (en) A kind of water solubility allopregnenolone derivative and application thereof
DE2329821A1 (en) MEDICINAL PRODUCTS CONTAINING CYSTEIN DERIVATIVES
US4599355A (en) Treatment of sleep disorders
EP0504180B1 (en) Glycyl-p-amino-pyridine for the treatment of senile dementia states
HU203766B (en) Process for producing estramustine-esters and pharmaceutical compositions containing them as active components
DE2512609A1 (en) PHARMACEUTICAL PREPARATION
DE60203878T2 (en) METHOD FOR THE PREVENTION OF AND TREATMENT OF BOVINE PAIN AND STOMACH DISEASES
WO2002064593A1 (en) 2-alkoxyphenyl substituted imidazotriazinones
JP3497554B2 (en) Novel purine derivatives and pharmaceutically acceptable salts thereof
DE69630073T2 (en) (-) Compounds containing hydroxycitrate with new therapeutic effects
DE2707072C2 (en) Derivatives of dithiepino [1,4] [2,3-c] pyrrole, their preparation and compositions containing them
CH678728A5 (en)
KR20130080364A (en) New modafinil derivatives and a pharmaceutical composition for treating or preventing inflammation comprising modafinil derivatives
JPH04270222A (en) Brain function improver

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR CA FI HU JP KP KR LK MC MG MW NO RO SD SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1990917637

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2070376

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1990917637

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1990917637

Country of ref document: EP